Effect of thrombocytosis on cardiovascular risk in rheumatoid arthritis
- 作者: Mazurov V.1,2, Melnikov E.1,2, Morozova K.2
-
隶属关系:
- North-Western State Medical University named after I.I. Mechnikov
- Clinical Rheumatology Hospital No. 25
- 期: 卷 15, 编号 2 (2023)
- 页面: 49-56
- 栏目: Original research
- URL: https://journals.rcsi.science/vszgmu/article/view/131104
- DOI: https://doi.org/10.17816/mechnikov116907
- ID: 131104
如何引用文章
详细
BACKGROUND: Patients with rheumatoid arthritis have a high level of comorbidity, and their most common and socially significant conditions are cardiovascular diseases, which represent a major cause of mortality. Currently, there are no data on the differences in cardiovascular risk scales in patients with rheumatoid arthritis depending on the presence or absence of thrombocytosis.
AIM: To assess and compare cardiovascular risk according to conventional scales in patients with thrombocytosis and normal thrombocytes.
MATERIALS AND METHODS: The study involved 85 patients diagnosed with rheumatoid arthritis: 40 with thrombocytosis [including 25 (62,5%) women] and 45 with normal thrombocytes [including 29 (64,4%) women]. The following scales were used to assess risk of cardiovascular complications: Systematic COronary Risk Evaluation with adjustment factor 1.5 (mSCORE), Reynolds Risk Score (RRS), QRESEARCH Cardiovascular Risk Algorithm (QRISK3), Assessing Cardiovascular Risk to Scottish Intercollegiate Guidelines Network / SIGN to Assign Preventative Treatment (ASSIGN).
RESULTS: The obtained findings have demontrated that according to the mSCORE and RRS scales the patients of both groups had almost identical parameters; however, according to the ASSIGN and QRISK3 high risk of cardiovascular complications has been detected nearly twice as frequently in the patients with rheumatoid arthritis and thrombocytosis in comparison with those with normal level of thrombocytes. It is also worth noting that more frequent determination of high risk of cardiovascular complications by the QRISK3 was statistically significant.
CONCLUSIONS: The QRISK3 calculation has shown significantly higher prevalence of high-risk cardiovascular complications among the patients with platelet counts >450 ∙ 109/l compared with those with platelet levels within the reference values. Thus, the QRISK3 scale can be considered as more informative for estimating risk of cardiovascular complications in rheumatoid arthritis.
作者简介
Vadim Mazurov
North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25
Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN 代码: 6823-5482
Scopus 作者 ID: 16936315400
Researcher ID: J-9643-2014
MD, Dr. Sci. (Med.), Professor, Аcademician of the RAS, Honored Scientist of the Russian Federation
俄罗斯联邦, Saint Petersburg; 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068Evgenii Melnikov
North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25
编辑信件的主要联系方式.
Email: melnikovzhenya@mail.ru
ORCID iD: 0000-0002-8521-6542
SPIN 代码: 4544-0596
аспирант кафедры терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи им. Э.Э. Эйхвальда
俄罗斯联邦, Saint Petersburg; 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068Kira Morozova
Clinical Rheumatology Hospital No. 25
Email: Kiramorozoba@mail.ru
ORCID iD: 0000-0002-4113-3104
MD, rheumatologist
俄罗斯联邦, 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068参考
- Mazurov VI, Gaidukova IZ, Belyaeva IB. Klinicheskaya revmatologiya. Rukovodstvo dlya vrachei. 3rd ed. Moscow: E-noto; 2021. 696 p. (In Russ.)
- Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219–229. doi: 10.1016/j.semarthrit.2020.11.005
- Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71(6):836–844. doi: 10.1136/annrheumdis-2011-200343
- Buttgereit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. Nat Rev Rheumatol. 2015;11(6):349–356. doi: 10.1038/nrrheum.2015.31
- Kim JW, Suh CH. Systemic manifestations and complications in patients with rheumatoid arthritis. J Clin Med. 2020;9(6):2008. doi: 10.3390/jcm9062008
- Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi: 10.1136/annrheumdis-2013-204223
- Kannayiram SS, Guraya A, Muojieje CC, et al. An analysis of rheumatoid arthritis hospitalizations. Cureus. 2020;12(12):e12344. doi: 10.7759/cureus.12344
- van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016;17:184. doi: 10.1186/s12891-016-1038-3
- England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036
- Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331. doi: 10.1136/ard.2009.113696
- Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27(2):136–140. doi: 10.1016/j.tcm.2016.07.006
- Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: a 15-year longitudinal Study. J Rheumatol. 2020;47(3):316–324. doi: 10.3899/jrheum.180726
- Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332. doi: 10.1136/annrheumdis-2014-205675
- Cooksey R, Brophy S, Kennedy J, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367–373. doi: 10.1016/j.semarthrit.2018.03.005
- Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England. PLoS One. 2016;11(3):e0151245. doi: 10.1371/journal.pone.0151245
- Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009;29(3):189–193. doi: 10.4103/0256-4947.51774
- Ehrenfeld M, Penchas S, Eliakim M. Thrombocytosis in rheumatoid arthritis. Recurrent arterial thromboembolism and death. Ann Rheum Dis. 1977;36(6):579–581. doi: 10.1136/ard.36.6.579
- Pines A, Kaplinsky N, Olchovsky D, et al. Recurrent transient ischemic attacks associated with thrombocytosis in rheumatoid arthritis. Clin Rheumatol. 1982;1(4):291–293. doi: 10.1007/BF02032089
- Casado Naranjo I, Martin Gonzalez R, Sancho Rieger J, et al. Transient ischaemic attacks associated with thrombocytosis in active rheumatoid arthritis. J Neurol Neurosurg Psychiatry. 1988;51(12):1599. doi: 10.1136/jnnp.51.12.1599
- Zhu L, Singh M, Lele S, et al. Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Sci Med. 2022;9(1):e000564. doi: 10.1136/lupus-2021-000564
- Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099
- Dessein PH, Semb AG. Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced? Ann Rheum Dis. 2013;72(11):1743–1746. doi: 10.1136/annrheumdis-2013-203911
- Colaco K, Ocampo V, Ayala AP, et al. Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review. J Rheumatol. 2020;47(6):928–938. doi: 10.3899/jrheum.190261
- Gerasimova EV, Popkova TV, Gerasimova DA, et al. Application of cardiovascular risk scales to identify carotid atherosclerosis in patients with rheumatoid arthritis. Terapevticheskii Arkhiv. 2021;93(5):561–567. (In Russ.) doi: 10.26442/00403660.2021.05.200787
- Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open. 2020;6(1):e001032. doi: 10.1136/rmdopen-2019-001032
- England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036
- Machlus KR, Thon JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014;165(2):227–236. doi: 10.1111/bjh.12758
- Garraud O, Cognasse F. Are platelets cells? And if yes, are they immune cells? Front Immunol. 2015;6:70. doi: 10.3389/fimmu.2015.00070
- Amaya-Amaya J, Montoya-Sanchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int. 2014;2014:367359. doi: 10.1155/2014/367359
- Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153–162. doi: 10.1016/j.blre.2014.10.003
- Mazurov VI, Melnikov ЕS, Bashkinov RA. Effect of platelets on the course of rheumatoid arthritis and cardiovascular risk. Terapiya. 2021;7(10(52)):78–88. (In Russ.) doi: 10.18565/therapy.2021.10.78-88